Molecular pathogenesis and therapeutic targets of lysosomal diseases
Tsuji, D.; Itoh, K.
Seikagaku. Journal of Japanese Biochemical Society 79(7): 678-682
2007
ISSN/ISBN: 0037-1017 PMID: 17763701 Document Number: 605262
Document emailed within 1 workday
Related Documents
2016: The 20th European Study Group on Lysosomal Diseases Workshop "Lysosomal storage disorders: problems of neurodegeneration and new therapeutic avenues" (Napoli, Italy, 1-4 Oct. 2015) Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 116(5): 125-129Wedgwood, A.; Pro, B.; Younes, A. 2005: The lymphomas: molecular pathways and novel therapeutic targets Current Hematology Reports 4(4): 324-334
Luján-Miras, R. 2005: Metabotropic glutamate receptors: new molecular targets in the treatment of neurological and psychiatric diseases Revista de Neurologia 40(1): 43-53
Eitner, F.; Floege, Jürgen. 2005: Therapeutic targets for prevention and regression of progressive fibrosing renal diseases Current Opinion in Investigational Drugs 6(3): 255-261
Herber, D.L. 2007: Molecular Targets in Cancer Therapy - Fourth Biennial Meeting. Mechanism and therapeutic reversal of immune suppression in cancer IDrugs: the investigational drugs journal 10(4): 227-229
Paolillo, R.; Boccella, N.; D'Apice, S.; Esposito, G.; Perrino, C. 2019: Lights and shadows of combined epigenomic and transcriptomic profiling to identify novel diagnostic, prognostic or therapeutic targets for cardiovascular diseases Giornale Italiano di Medicina del Lavoro Ed Ergonomia 41(4): 328-332
Lansbury, P.T. 1995: Consequences of the molecular mechanism of amyloid formation for the understanding of the pathogenesis of Alzheimer's disease and the development of therapeutic strategies Arzneimittel-Forschung 45(3a): 432-434
Zasukhina, G.D. 1987: Molecular-genetic mechanisms of the pathogenesis of human diseases related to disorders of processes involved in the repair of DNA damage Arkhiv Patologii 49(1): 3-9
Genyk, S.N.; Baĭsa, A.V. 1985: Pathogenesis of the therapeutic effect of hemosorption in patients with obliterating diseases of the vessels of the lower extremities Klinicheskaia Meditsina 63(11): 15-18
Suzuki, Y. 2010: Chemical chaperone therapy:a new molecular therapeutic approach to neurogenetic diseases No to Hattatsu 42(2): 134-137
Khasman, E.L.; Andreev, S.D.; Zaĭtseva, L.G.; Daurova, T.T. 1982: Role of lysosomal enzymes in the pathogenesis of adhesions Arkhiv Patologii 44(10): 93
Maianskiĭ, D.N.; Tsyrendorzhiev, D.D.; Rupakova, S.A. 1987: Lysosomal enzymes of phagocytizing cells in the pathogenesis of inflammation Voprosy Meditsinskoi Khimii 33(5): 48-52
Maianskii, D.N.; Viksman, M.E.; Makarov, M.P. 1972: Role of lysosomal enzymes in the pathogenesis of the transplant vs host reaction Patologicheskaia Fiziologiia i Eksperimental'naia Terapiia 16(2): 42-48
Gorman, J.M. 2003: New molecular targets for antianxiety interventions Journal of Clinical Psychiatry 64(Suppl 3): 28-35
Coleman, R. 2018: Setting the scene, setting the targets. The Joint United Nations Programme on HIV/AIDS prevention targets of 2016 and estimating global pre-exposure prophylaxis targets Sexual Health 15(6): 485-488
Bogush, T.A.; Dudko, E.A.; Bogush, E.A.; Polotskiĭ, B.E.; Tiuliandin, S.A.; Davydov, M.I. 2012: Tamoxifen molecular targets different from estrogen receptors Antibiotiki i Khimioterapiia 57(1-2): 50-58
Ferguson, W.W.; Starling, J.R.; Wangensteen, S.L. 1972: Role of lysosomal enzyme release in the pathogenesis of stress-induced gastric ulceration Surgical Forum 23(0): 380-382
Santoro, F.; Vassena, L.; Lusso, P. 2004: Chemokine receptors as new molecular targets for antiviral therapy New Microbiologica 27(2 Suppl 1: 17-29
Mitsudomi, T. 2002: Molecular lesions as targets for diagnosis and therapy of lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(Suppl 1): 112-116
Sterlinko Grm, H.; Banks, L. 2004: HPV proteins as targets for therapeutic intervention Antiviral Therapy 9(5): 665-678